Nabriva Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
H. Hogan
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.3yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
CEO
H. Hogan (60 yo)
less than a year
Tenure
Mr. H. Michael Hogan III is Chief Executive Officer of Nabriva Therapeutics plc from July 6, 2023. He serves as Director of Metacrine, Inc. since March 23, 2023. He is Director of Otonomy, Inc. from Februa...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | 6.2yrs | US$40.00k | 0.042% $ 663.6 | |
| Chief Executive Officer | less than a year | no data | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| General Counsel & Secretary | 2.2yrs | no data | no data |
1.3yrs
Average Tenure
62yo
Average Age
Experienced Management: NTY's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | 6.4yrs | US$40.00k | 0.042% $ 663.6 | |
| Independent Chairman of the Board | 6.4yrs | US$90.00k | 0.013% $ 201.1 | |
| Independent Director | 2.4yrs | US$50.00k | 0.0089% $ 139.5 | |
| Independent Director | 6.4yrs | US$65.00k | 0.014% $ 221.0 | |
| Director | 2.7yrs | US$579.23k | 0.041% $ 641.4 | |
| Independent Director | 6.4yrs | US$55.00k | 0.019% $ 295.7 | |
| Director | 5.3yrs | US$753.56k | 0.26% $ 4.1k | |
| Independent Director | 2.4yrs | US$47.50k | 0.011% $ 176.5 | |
| Independent Director | 6.4yrs | US$52.50k | 0.012% $ 192.0 |
6.4yrs
Average Tenure
62yo
Average Age
Experienced Board: NTY's board of directors are considered experienced (6.4 years average tenure).